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Prevention of Toxic Environmental Illness
in the Twenty-First Century
by Philip J. Landrigan*
Previous introductions of new technologies have frequently resulted in unanticipated occupational and
environmental illness. Prevention ofsuch illness in the twenty-first century requires stringent application
oftwo fundamental principles ofpublic health: evaluation of new technologies before their introduction,




A major challenge to technologic development in the
twenty-first century will be to prevent environmental
and occupational diseases, which too often accompanied
the introduction of new technologies in centuries past.
The catalogue ofdiseases caused by new technologic
developments includes lead poisioning, which occurred
in the ancient Greeks and Romans usinglead acetate to
sweeten wine (1); mercury poisoning, present in the
Almaden Spanish miners during the Middle Ages (2);
lead poisoning in Renaissance potters (3); black lung in
coal miners (2); and silicosis in English foundry workers
andgrindersduringthe IndustrialRevolution (4). Inthe
modern era industrial toxic conditions include bladder
cancer in dye workers (5), phossy jaw in matchmakers
(6), mesothelioma and lung cancer in asbestos workers
(7), encephalopathyandneurotoxicityinpesticide manu-
facturers (8,9), leukemia and solid tumors in persons
exposed to ionizing radiation (10), and leukemia and
lymphoma in benzene workers (11,12).
Typically, when a new technology is first introduced,
it is hailed as safe. No associated disease is seen in the
initial months or years following its use; presumably,
this is due either to the fact that a latency (incubation)
period must elapse before the appearance of illness or
that anillness associated withthetechnologyhassimply
notyetbeenrecognized. Whendisease associatedwith a
new technology is finally observed, the symptoms asso-
ciatedwithhigh-dose exposure areusuallythefirsttobe
perceived. Frequently, initial recognition is made by an
astute clinician (13) who sees a new disease or a new
association such as scrotal cancer in chimney sweeps
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(14), angiosarcoma ofthe liverin vinyl chloride workers
(15), or lung cancer in workers exposed to bis-
chloromethyl ether (16). Initial clinical recognition is
followed by epidemiologic confirmation and toxicologic
corroboration. Additionally, and with increasing fre-
quency, quantitative risk assessment is undertaken and
a dose-response relationship is established.
Recent Environmental Diseases in
Industry
Two recent examples ofenvironmental diseases that
resulted from the introduction of new technologies are
the kepone disaster, associated with the manufacture of
anewpesticide (9), and epidemic neurologicparalysis of
the urinary bladder, associated with the introduction of
a new catalyst in plastic manufacture (17). Details of
these two environmental episodes are as follows.
Kepone Episode
Kepone (decachlorooctahydro 1,3,4-metheno-2H-
cyclobuta (cd) pentalen-2-one) is a chlorinated hydro-
carboninsecticide. ItwasdevelopedbytheAlliedChem-
ical Company in the early 1950s and was registered as a
pesticidein 1955. Insucceedingyears Kepone was made
intermittently by Allied Chemical, but in 1973 the com-
pany discontinued allproduction ofKepone and entered
into an exclusive production contract with Life Sciences
Products Company (LSPC), a newly incorporated firm
inHopewell, VA. From 1974throughJuly 1975, LSPCin
Hopewell was the world's sole producer of Kepone.
OnJuly 11, 1975, aninternist inHopewell sent ablood
samplefromanLSPCworkerwithseveretremorstothe
Centers for Disease Control Toxicology Laboratory for
Kepone analysis. The result showed a highly elevated
Kepone level of 7.5 parts per million (ppm); the normalP. J. LANDRIGAN
level is zero. Follow-up field investigations on July 22
and 23 by the Epidemiology Bureau, Virginia State
Health Department, revealed massive contamination of
the plant site and ahigh prevalence ofunusual illness in
workers. Officials of the State Health Department
closed the plant on July 24.
To investigate the clinical and epidemiologic features
of this outbreak, a listing was obtained from company
records of all 148 persons who had been employed at
LSPC in the 16 months of its operation (33 current
employees and 115 former). One hundred fifty-
three (90%) of these employees (all current and 100
former) were located, and a questionnaire was com-
pleted for each worker relating to general health, occu-
pational exposure, and possible job-related illness. A
brief physical examination was performed on each
worker, and a venous blood sample was obtained to
determine the Kepone level.
A bizarre neurologic syndrome was found in the af-
fected workers with the average interval between start
ofemployment at LSPC and onset ofsymptoms being 6
weeks. The two most prominent features were a sen-
sation ofnervousness and the occurrence oftremor. In
severe cases, tremor was present at rest; in all cases it
was increased by using the affected limbs. The hands
were chiefly involved, but fine tremor of the head and
trembling of the entire body were also noted. The
tremor interfered with ordinary activities such as eat-
ing, writing, and using simple hand tools. Greatly exag-
gerated startle responses were noted in persons se-
verely affected.
Visual difficulty, characterized by an inability to fix-
ate and focus, was also a prominent finding. On exam-
ination, patients were noted to have bursts of op-
soclonus, usually horizontal, but occasionally multi-
directional as well. Occasionally, a mild degree of
cerebellar ataxia was noted. Personality changes were
also observed with the most common being irritability,
difficulty with recent memory, and mild depressionthat
occasionally ranged to disorientation.
Epidemic Neurogenic Bladder Dysfunction
On March 28, 1978, the Board of Health in Marble-
head, MA, notified the Massachusetts Department of
PublicHealththat 11 workersemployedinafactorythat
produced polyurethane foam automobile seat cushions
had been examined at a local hospital emergency room.
They complained ofurinary difficulties ofrecent onset.
Thesedifficulties includedhesitancyinurination, strain-
ing to void, decreased force of urinary stream, and
increased duration of urination. Several volunteered
that they had lost the urge to urinate and voided only
once a day or by habit.
Theclusteringandsuddenonsetofthepatients'illness
suggested an occupational etiology. Accordingly, all
available workers, symptomatic and asymptomatic,
were interviewed. Work practices and plant processes
were evaluated. The analysis revealed that a new cata-
lyst, dimethylaminopropionitrile (DMAPN), had been
added to the polyurethane on one of the two assembly
lines in August 1977, and it was used irregularly until
December. From December 1977 through March 1978,
both assembly lines at the plant had used the new
catalyst.
Intheepidemiological analysis, datawere obtained on
208 of the 230 plant workers. The first case of bladder
dysfunction occurred in August 1977 (shortly after the
introduction of DMAPN) in a female mold cleaner who
worked close to an area where hot polyurethane foam
with the new catalyst was removed from molds. The
frequency ofsubsequent cases increased roughly in par-
allel with the use of the catalyst.
Thehighestincidence ofbladderdysfunction occurred
in assembly line workers. Among the 166 production
workers, 104 (63%) had symptoms. No cases occurred
among the 42 nonproduction employees. Twenty cases
were noted in 36 women production workers (55.6%),
and 84 cases in 130 men (64.5%).
Fivemen andthreewomenwerereferredfordetailed
neurologic andurologicevaluation. Onneurologic exam-
ination, seven ofthese eight patients had abnormalities
affecting the distal lower extremities. Five had a sen-
sory neuropathy and two had a mixed sensorimotor
neuropathy. On electrophysiologic testing, one patient
had prolonged peroneal latency and reduced evoked
muscle action potentials; these findings were cor-
roborated by marked muscle atrophy in the feet. Three
patients had a slowing of sural sensory nerve con-
duction, and one showed a reduced amplitude of the
sural nerve action potential. There patients had pro-
longed sacrallatency, and two ofthe three had evidence
by electromyography of partial denervation of the ex-
ternal anal sphincter.
Discussion
An exponential increase has occurred since World
War II in developing and producing new synthetic
chemicals. Duringthis40-yearperiod, chemicalproduc-
tion capacity has increased worldwide by 350-fold (18).
More than 1000 new chemical compounds are now pro-
duced each year; they are added to the 60,000 pure
chemicals and the two million mixtures, formulations,
and blends already in commercial use (19).
Anunfortunate consequence ofthiswidespread intro-
duction of new chemical technologies into the human
environment has been the wide occurrence ofnew occu-
pational and environmental diseases. Such illnesses are
highly prevalent in American society today.
Recent data from New York state indicate that occu-
pationally related exposures are responsible each year
for 5,000 to 7,000 deaths and for 35,000 new cases of
illness (not including work-related injuries) (20). The
deaths due to occupational disease include 3,700 deaths
from cancer (10% of 37,000 cancer deaths in the state
each year), and between 1,000 and 2,800 deaths from
pulmonary, cardiovascular, renal, and neurologic dis-
eases (1-3% of 95,000 deaths from these causes each
year).
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Crudenationalestimatesoftheburdenofoccupational
disease inthe U.S. maybedevelopedbymultiplyingthe
New York state data by a factor of 10. New York state
contains slightlylessthan 10%ofthenation'sworkforce,
and it includes a broad mix ofemployment in the manu-
facturing service and agricultural sectors. Thus, it may
be calculated that occupational disease is responsible
eachyearintheU.S. for50,000to70,000deaths, andfor
approximately 350,000 new cases of illness.
Several factors account for this high prevalence of
environmental and occupational disease resulting from
technologic innovation. They are as follows:
. Inadequate evaluation of new technologies before
theircommercialintroduction. Recentdatafromthe
NationalAcademy ofSciences indicatethat nomore
than 20% of commercial chemicals have had ade-
quate premarket toxicologic evaluation (21). En-
forcing the provisions ofthe Toxic Substances Con-
trol Act (19) has been a substantial failure.
* Inadequate training ofphysicians and other health
providers in the recognition of occupational and
environmental disease. The average physician in
trainingin the United States receives atotal ofonly
4 hr of instruction in occupational medicine (22).
Consequently, few physicians take adequate occu-
pational histories (23) or are skilled in diagnosing
occupational and environmental illness.
* Inadequate surveillance of populations exposed to
newly introduced technologies.
Unless these continuing multiple failures of pre-
vention are rectified, we must recognize that the intro-
duction ofnew technologies in the twenty-first century
will almost inevitably result in the development ofnew
forms of environmental and occupational illness.
Techniques for preventing diseases caused by new
technologies are not new. They were developed in the
nineteenth century during the era ofsanitary reform in
England (2). They are proper evaluation of new tech-
nologies before their commercial introduction and
proper surveillance of exposed persons following the
introduction of new technologies.
If these two fundamental mechanisms for the pre-
vention of environmental and occupational illness are
established in this century and carefully applied in the
next, the risk of new environmental and occupational
illness will be reduced. Ifnot, history will repeat itself.
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